Best Agrolife Ltd. · NSE:BESTAGRO
Best Agrolife — FY2026 Earnings Presentation
20 slides from Best Agrolife's earnings presentation, May 28, 2026
Slide 1: Corporate Presentation intimation to stock exchanges
Affotitelimited CIN : L74l 10D11992P1C116773 WBest 28thMaYr2026 To National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block-G, 25th Floor, P.J. Towers, Bandra - Kurla Complex Dalal Street, Mumbai-400001 Bandra (E), Mumbai-400051 SCRIP CODE: 539660 SCRIP ID: BESTAGRO Sub: Intim
Slide 2: Financial Highlights FY25-26
Financial Highlights FY25-26
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the company’s activities as at the date of the presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Company Snapshot
Company Snapshot 15th 40 9 10,000 Warehouses Key Patented Dealers Largest Indian 21 States Products Agrochemical Company* 4 530+ 800+ Manufacturing units Formulations Employees 7000 MTPA Technical Registrations 35500 KL Formulation *Agropages Top 20 Indian Agrochemical Companies
Slide 5: Management Comment
Management Comment “During FY26, we expanded our specialty and patented product portfolio with the launch of three patented formulations, BestmanTM, FetagenTM and Shot DownTM. As part of our ongoing innovation-led strategy, we will be launching four additional patented products in FY’27; FluzamTM, M
Slide 6: Key Patented Products
Key Patented Products RONFENTM TRICOLORTM NEMAGENTM SHOT DOWNTM WARDEN EXTRATM Insecticide (SC) Fungicide (SC) Insecticide (SC) Herbicide (ME) Insecticide + Fungicide (FS) Pyriproxyfen - 8% Trifloxystrobin - 10% Chlorantraniliprole - 4.5% Haloxyfop-R Methyl - 12.8% Trifloxystrobin - 6% Dinotefuran -
Slide 7: Building a Branded Business
Building a Branded Business Branded v/s Institutional Sales Contribution of Patented products in Branded Sales 44% 36% 34% 37% 41% 64% 66% 63% 56% 30% 9% 21% FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Branded Institutional Sales
Slide 8: Fluzam & Cubax Power Extra
FLUZAMTM & CUBAX POWER EXTRATM FluzamTM Cubax Power ExtraTM FluzamTM is a patented triple- Cubax Power ExtraTM combines action seed treatment the power of Spiromesifen 15% powered by Trifloxystrobin 4% + Hexythiazox 2.2% + + Fluxapyroxad 6.66% + Abamectin 1.15% w/w SC for Clothianidin 25% FS for ear
Slide 9: Bio-Fertilizers
Bio-Fertilizers PunctualTM SprinkTM Richgrow GoldTM TornetTM EmproleTM It is an organic potassium It is a highly concentrated It harnesses the natural power of It is a powerful bio- It is a plant-based amino acid solution derived from Ascophyllum nodosum 15% based seaweed to stimulate vigorous stimu
Slide 10: Key Highlights
Key Highlights 01 Financial Performance 1. Gross Margins: restructured teams 4. Inventory Management: • Improved compared to the • Inventory in Q4 FY25: ₹778 Cr previous year 3. Cash Flow & Financial Health: • Inventory in Q4 FY26: ₹651 Cr • Positive overall cash flow 2. Operating Expenses (OPEX): •
Slide 11: Product Achievements in FY26
Product Achievements in FY26 01 Received 7 patent grants • Nano Urea • Combination of Spinosad + Fipronil + Pyriproxyfen • Combination of Pinoxaden + Metsulfuron methyl + 2,4-D • Combination of Trifloxystrobin + Valifenalate + Difenoconazole • Combination of Nitenpyram + Pymetrozine or Dinotefuran +
Slide 12: Consolidated P&L for Q4 FY26
Consolidated P&L for Q4 FY26 Value (INR Cr) Q4 FY26 Q4 FY25 Y-o-Y Q3 FY26 Revenue from Operations 156 274 (43)% 203 Other Income 1 1 1 Total Revenue 157 275 (43)% 204 Cost of Goods Sold 121 212 138 Employee Benefits Expense 25 23 25 Other Operating Expenses 37 35 36 Total Expenses 183 270 199 EBITDA
Slide 13: Financial Snapshot Q4
Financial Snapshot Q4 Revenue from operations EBITDA* 274 Q4 FY25 Q4 FY26 (₹ Crore) (₹ Crore) 156 4 -27 Q4 FY25 Q4 FY26 PAT EPS Q4 FY25 Q4 FY26 Q4 FY25 Q4 FY26 -22 -37 -0.62 (₹ Crore) -1.05 *EBITDA is calculated excluding other income
Slide 14: Q4 & FY26 Performance
Q4 & FY26 Performance Q4 FY26 Performance • Revenue from Operations: The company reported revenue from operations of ₹156 crore in Q4 FY26, compared to ₹274 crore in Q4 FY25. • Gross Margin: Gross margin remained stable at ~23%, reflecting resilience in product mix and pricing despite softer volumes
Slide 15: Key Ratios
Key Ratios Debt to Equity (x) Net Debt to Equity (x) 1.06 0.89 0.90 0.97 0.62 0.56 0.48 0.44 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Current Ratio (x) ROCE 1.53 26% 1.35 1.37 1.21 15% 13% 5% FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 *Formulae: ROCE= EBIT/ Capital Employed*100 (Capital Employed = Total
Slide 16: Working Capital Movement
Working Capital Movement 278 248 243 223 212 188 178 173 165 FY24 FY25 FY26 Inventory Days Cash coversion days Working capital Days
Slide 17: Consolidated P&L for FY26
Consolidated P&L for FY26 Value (INR Cr) FY26 FY25 Revenue from Operations 1,257 1,814 Other Income 5 5 Total Revenue 1,261 1,819 Cost of Goods Sold 876 1,283 Employee Benefits Expense 99 107 Other Operating Expenses 181 224 Total Expenses 1,157 1,614 EBITDA* 100 200 EBITDA Margin (%) 8% 11% Depreci
Slide 18: Consolidated Balance sheet
Consolidated Balance sheet Value (INR Cr) As on Mar 31, 2026 As on Mar 31, 2025 Equity And Liabilities Share Holders Fund 769 758 Non-current Liabilities • Long Term Borrowings 27 14 • Other Financial Liabilities 32 41 Total Non-current Liabilities 59 55 Current Liabilities • Short Term Borrowings 4
Slide 19: Experienced Management Team
Experienced Management Team Mr. Vimal Alawadhi Mr. P. N. Karlekar Mr. N Surendra Sai Mr. Vikas Jain Managing Director Non Executive Director Whole Time Director Chief Financial Officer A t rue visionary and a pa ssionat e A chemical Engineer from UDCT- one of A pass ionate t echnolo gist and A seaso
Slide 20: Thank You
Thank You Contact Us: ir@bestagrolife.com (Investor Relations) DISCLAIMER This presentation includes certain forward looking statements and information including statements concerning the outlook for business. The statements are based on certain expectations, assumptions, anticipated developments an